Safety profile of camrelizumab: An analysis based on literature and database review
Yi Huang, Wei Li · 2026
Read Safety profile of camrelizumab: An analysis based on literature and database review by Yi Huang, Wei Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354252.txt.
Description
Huang and Li, in a 2026 safety review, gather what is known about side effects of camrelizumab, a cancer immunotherapy drug used mainly in China. Real-world safety reports are scarce, so the team mined the World Health Organization's global side effect database and published case reports from the drug's first years on the market.
Six hundred reports sat in the global database, nearly all from Asian patients and most from men. Blood problems led the list, including bone marrow suppression and low platelet counts, followed by skin reactions such as rash and itching. A growth of tiny blood vessels on the skin is a signature side effect of this drug. Rare but serious events included heart muscle inflammation and severe blistering skin reactions. Case reports added timing: effects appeared a median of eight weeks in. The authors give clinicians a watch list, stressing blood counts, skin, and heart checks.
Catalog record
| CREATOR | Yi Huang, Wei Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32963 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |